Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 38 (1) , 1627-1632
Abstract
To compare the therapeutic effects of locoregional deep hyperthermia combined with intravesical chemotherapy with those of intravesical chemotherapy alone in patients with intermediate-/high-risk non-muscle invasive bladder cancer (NMIBC). To evaluate the impact of thermal dose in hyperthermia treatment. We analyzed data retrieved from the medical records of patients with intermediate-/high-risk NMIBC treated with intravesical mitomycin (IM group) or locoregional deep hyperthermia combined with intravesical mitomycin (CHT group) at a single tertiary care hospital between May 2016 and June 2019. The primary and secondary endpoints were the recurrence-free survival rate and progression-free survival rate, respectively. Thermal dose was evaluated and adverse events were also recorded. In total, 43 patients (CHT: 18 patients, IM: 25 patients) were enrolled. The median follow-up durations were 14 and 23 months, respectively. The recurrence rate at 12 months was significantly lower in the CHT group than in the IM group (11.1% vs. 44%, p = .048); this trend persisted at 24 months (CHT: 11.1%, IM: 48%; p = .027). The recurrence-free survival was also significantly higher in the CHT group than in the IM group (p = .028). No tumor recurrence was noted in patients who received a thermal dose of ≥4 CEM43. All adverse events were well tolerated, and there was no treatment-related mortality. Intravesical chemotherapy combined with locoregional deep hyperthermia for intermediate-/high-risk papillary NMIBC can significantly decrease the recurrence rate relative to that observed after intravesical chemotherapy alone.Keywords
This publication has 27 references indexed in Scilit:
- A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancerInternational Journal of Hyperthermia, 2014
- Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinomaMedical Physics, 2012
- Long‐term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin‐C alone as adjuvant treatment for non‐muscle‐invasive bladder cancer (NMIBC)BJU International, 2010
- Mechanisms of recurrence of Ta/T1 bladder cancerThe Annals of The Royal College of Surgeons of England, 2010
- Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment StrategyEuropean Urology, 2009
- Economic aspects of bladder cancer: what are the benefits and costs?World Journal of Urology, 2009
- Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancerWorld Journal of Urology, 2009
- Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancerScandinavian Journal of Urology and Nephrology, 2008
- Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized StudyCancer Research and Treatment, 2005
- Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and ToxicityJournal of Urology, 2003